🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1/ 🚨Happy to share our piece of work entitled “Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types”, just in The Lancet Oncology Effort co-led by Rashad Nawfal, MD with exceptional mentorship Solange Peters Tom Powles Toni Choueiri, MD

1) Excited to share our work The Lancet Oncology on the landscape of subsequent therapies in perioperative IO trials across cancer types. Effort co-led with Karl Semaan, MD, MSc with great mentorship from Solange Peters Tom Powles Toni Choueiri, MD and co-authors! Link: thelancet.com/journals/lanon…

Great presentation from Dana-Farber Lank Center for Genitourinary Oncology urologist, research fellow and superstar Clara Steiner working on KIM-1 with great mentorship from Wenxin (Vincent) Xu !

Tour de force presentation on HIF2A expression and clinical outcomes in ccRCC and sarc-Rcc by Dana-Farber Lank Center for Genitourinary Oncology superstar Rashad Nawfal, MD! Sylvan Baca MD PhD (Hiring!) Dana-Farber #FreedmanLab

Our rising star Wassim Daoud Khatoun taking the stage to discuss the association between IL7 SNP & irAE. Sky is the limit! Dana-Farber Lank Center for Genitourinary Oncology OncLive.com OncoAlert

Spectacular presentation from Dana-Farber Lank Center for Genitourinary Oncology superstar/computational biologist Karl Semaan, MD, MSc. First work to show longitudinal monitoring of NEPC using liquid biopsy! With super mentorship from Sylvan Baca MD PhD (Hiring!) #FreedmanLab

Excellent presentation from the #IMDC superstar lead fellow Razane El Hajj Chehade #RHC assessing low vs low-intermediate substrata of IMDC risk groups! Daniel Heng Sylvan Baca MD PhD (Hiring!) Dana-Farber

My dear friend Neeraj Agarwal, MD, FASCO presenting #TALAPRO2 final OS analysis: TALA + ENZA significantly improved OS vs PBO + ENZA in 1L mCRPC (HR 0.796). rPFS benefit sustained (HR 0.667). Safety consistent with prior reports. Phenomenal! André P. Fay #KarimFizazi ASCO #GU25 OncoAlert

So proud of mentees Razane El Hajj Chehade, Karl Semaan, MD, MSc, Rashad Nawfal, MD, and Marc Eid for their fantastic talks at ASCO #GU25. Their translational projects should lead to better outcomes for patients with kidney or prostate cancer.

Sky is the limit with our phenomenal Karl Semaan, MD, MSc discussing plasma cfChIP in detecting and monitoring NE transformation in #prostatecancer! Excited to see where this outstanding physician-scientist will match! ASCO #GU25 Sylvan Baca MD PhD (Hiring!) #FreedmanLab Razane El Hajj Chehade Marc Eid

Elegant presentation from Alex Wyatt on the evolution of ctDNA detection and characterization! Session chaired by Dana-Farber Lank Center for Genitourinary Oncology's joaquim bellmunt and Barts Experimental Cancer Medicine Centre 's Bernadett Szabados #GU25 ASCO OncoAlert OncLive.com

How can ctDNA be used to improve clinical staging for UTUC? Outstanding discussion by Roger Li ASCO #GU25 Moffitt Cancer Center OncoAlert

How can urine and plasma liquid biopsy be used across the spectrum of urothelial carcinoma? Terrific discussion by Gillian Vandekerkhove ASCO #GU25 joaquim bellmunt Bernadett Szabados OncoAlert

Terrific work by Tom Powles !! With >2 years of follow-up, 1L EV+P maintains superior OS and PFS vs chemo in la/mUC. cCR rate doubled (30.4% vs 14.5%), with longer response durability and no new safety signals. EV+P remains SOC! Barts Cancer Institute (Queen Mary) Shilpa Gupta ASCO #GU25 OncoAlert

Update on #COSMIC313 trial presented by the one and only Laurence Albiges: C+N+I showed sustained PFS & ORR benefits over P+N+I in 1L intermediate/poor risk pts. OS was similar between arms (HR 1.02). Addition of Cabo to N+I overcomes M2-like macrophage-mediated immune suppression

Some snapshots of our super stars Dana-Farber Lank Center for Genitourinary Oncology post-docs work at #GU25 such as Marc Machaalani Clara Steiner Renee Maria Saliby Rashad Nawfal, MD Emre Yekedüz Karl Semaan, MD, MSc Eddy Saad Razane El Hajj Chehade …..missing many ! OncoAlert Dana-Farber Dana-Farber News

⭐️Future of GU oncology is VERY bright. LOVED learning about the cutting edge research of the Fellows and trainees at OncLive.com GU Fellows forum at #GU25. Also really enjoyed joining global GU leaders and superb mentors Dr. Choueiri Dr. McKay and Dr. Garcia as they provided

If you are at #AACR25 and interested in #pancreaticcancer and #liquidbiopsy, check out our poster #5926 section 32 from 2-5pm today.

Rafeh Naqash Shares Article on Immune Checkpoint Inhibitors For Patients With Autoimmune Neurologic Disorders Rafeh Naqash, MD JAMA Network Open Marc Machaalani Razane El Hajj Chehade oncodaily.com/science/rafeh-… #Cancer #CancerResearch #MedX #MedNews #MedEd #ImmuneCheckpointInhibitors

Comorbidity Burden and Effectiveness of Immunotherapy in Metastatic Renal Cell Carcinoma clinical-genitourinary-cancer.com/article/S1558-… This study investigated the impact of pre-existing medical conditions (comorbidities) on outcomes for 304 patients with metastatic renal cell carcinoma (mRCC)